Jochen Lehmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jochen Lehmann has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Christoph Enzensperger
Institute of Organic Chemistry and Macromolecular Chemistry, Friedrich-Schiller-Universität Jena, D-07743 Jena, Germany
4 shared publications - Dina Robaa
Stiftung des öffentlichen Rechts an der Martin-Luther-Universität Halle-Wittenberg
4 shared publications Michael Decker
Institute of Pharmacy, Institute of Pharmacology and Toxicology, and Institute of Clinical Chemistry, Friedrich-Schiller-University Jena, D-07743 Jena, Germany, Center of Drug Discovery, China Pharmaceutical University, 210009 Nanjing, People's Republic of China, and Medicinal Chemistry Program, McLean Hospital, Harvard Medical School, Belmont, Massachusetts 02478
4 shared publicationsChristoph Enzensperger
Institute of Organic and Macromolecular Chemistry, Univerity of Jena , Humboldtstrasse 10, 07743 Jena, Germany
3 shared publications- Martin Nieger
University of Helsinki
3 shared publications Sixun Peng
State Key Laboratory of Natural Medicines China Pharmaceutical University Nanjing P. R. China
3 shared publications
Latest Publications
- 17 August 2015
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (16) , 6710-6715
Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders
Neurodegenerative diseases represent a challenge for biomedical research due to their high prevalence and lack of mechanism-based treatments. Because of the complex pathology of neurodegenerative disorders, multifunctional drugs have been increasingly recognized as potential treatments. We identified homobivalent γ-carbolinium salts as potent inihitors of both cholinesterases, N-methyl-d-aspartate receptors, and monoamine oxidases. Homobivalent γ-carbolines displayed similar structure–activity relationships on all tested targets and may present promising designed multiple ligands for the treatment of neurodegenerative disorders.
- 17 August 2015
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (16) , 6710-6715
Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders
Neurodegenerative diseases represent a challenge for biomedical research due to their high prevalence and lack of mechanism-based treatments. Because of the complex pathology of neurodegenerative disorders, multifunctional drugs have been increasingly recognized as potential treatments. We identified homobivalent γ-carbolinium salts as potent inihitors of both cholinesterases, N-methyl-d-aspartate receptors, and monoamine oxidases. Homobivalent γ-carbolines displayed similar structure–activity relationships on all tested targets and may present promising designed multiple ligands for the treatment of neurodegenerative disorders.
- 6 November 2013
- Published by Wiley in Archiv der Pharmazie
- Vol. 346 (12) , 865-871
Tacrine–Flurbiprofen Hybrids as Multifunctional Drug Candidates for the Treatment of Alzheimer's Disease
Five tacrine–flurbiprofen hybrid compounds (3a–e) were synthesized as multi‐target‐directed compounds for the treatment of Alzheimer's disease. Compared to tacrine, two compounds (3dand3e) showed better acetylcholinesterase (AChE) inhibitory activity and others (3b–e) better or the same butyrylcholinesterase (BuChE) inhibitory activity. Notably,3dshowed a mixed‐type inhibitory action for AChE, indicating a “dual‐binding site action” of both toward the catalytic active site (CAS) and the peripheral anionic site (PAS), whereas for BuChE, a competitive inhibitory action was observed. Furthermore, a cell‐based assay on amyloid‐β inhibition demonstrated that the selected target compound3deffectively inhibits the formation of amyloid‐βin vitro.
- 6 November 2013
- Published by Wiley in Archiv der Pharmazie
- Vol. 346 (12) , 865-871
Tacrine–Flurbiprofen Hybrids as Multifunctional Drug Candidates for the Treatment of Alzheimer's Disease
Five tacrine–flurbiprofen hybrid compounds (3a–e) were synthesized as multi‐target‐directed compounds for the treatment of Alzheimer's disease. Compared to tacrine, two compounds (3dand3e) showed better acetylcholinesterase (AChE) inhibitory activity and others (3b–e) better or the same butyrylcholinesterase (BuChE) inhibitory activity. Notably,3dshowed a mixed‐type inhibitory action for AChE, indicating a “dual‐binding site action” of both toward the catalytic active site (CAS) and the peripheral anionic site (PAS), whereas for BuChE, a competitive inhibitory action was observed. Furthermore, a cell‐based assay on amyloid‐β inhibition demonstrated that the selected target compound3deffectively inhibits the formation of amyloid‐βin vitro.
- 27 April 2012
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (9) , 4309-4321
Tacrine–Ferulic Acid–Nitric Oxide (NO) Donor Trihybrids as Potent, Multifunctional Acetyl- and Butyrylcholinesterase Inhibitors
In search of multifunctional cholinesterase inhibitors as potential anti-Alzheimer drug candidates, tacrine–ferulic acid–NO donor trihybrids were synthesized and tested for their cholinesterase inhibitory activities, release of nitric oxide, vasodilator properties, cognition improving potency, and hepatotoxicity. All of the novel target compounds show higher in vitro cholinesterase inhibitory activity than tacrine. Three selected compounds (3a, 3f, and 3k) produce moderate vasorelaxation in vitro, which correlates with the release of nitric oxide. Compared to its non-nitrate dihybrid analogue (3u), the trihybrid 3f exhibits better performance in improving the scopolamine-induced cognition impairment (mice) and, furthermore, less hepatotoxicity than tacrine.
- 27 April 2012
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (9) , 4309-4321
Tacrine–Ferulic Acid–Nitric Oxide (NO) Donor Trihybrids as Potent, Multifunctional Acetyl- and Butyrylcholinesterase Inhibitors
In search of multifunctional cholinesterase inhibitors as potential anti-Alzheimer drug candidates, tacrine–ferulic acid–NO donor trihybrids were synthesized and tested for their cholinesterase inhibitory activities, release of nitric oxide, vasodilator properties, cognition improving potency, and hepatotoxicity. All of the novel target compounds show higher in vitro cholinesterase inhibitory activity than tacrine. Three selected compounds (3a, 3f, and 3k) produce moderate vasorelaxation in vitro, which correlates with the release of nitric oxide. Compared to its non-nitrate dihybrid analogue (3u), the trihybrid 3f exhibits better performance in improving the scopolamine-induced cognition impairment (mice) and, furthermore, less hepatotoxicity than tacrine.
- 5 April 2012
- Published by Georg Thieme Verlag KG in Arzneimittelforschung
- Vol. 62 (05) , 252-260
Molecular Combination of the Dopamine and Serotonin Scaffolds Yield in Novel Antipsychotic Drug Candidates - Characterization by in vivo Experiments
Serotonin and dopamine play an important role in the aetiology of schizophrenia. Combination of the structural scaffolds of both neurotransmitters in a single molecule lead to aromatic [d,g]-bisannelated azecine derivatives, which have been shown to be nanomolar to subnanomolar dopamine D1-D5 receptor antagonists with a preference for the D1 family. In this work the potential antipsychotic activity of some azecine derivatives was predicted by their dopamine receptor affinities obtained in vitro from radioligand binding experiments and conclusively confirmed in vivo (rats) by applying a conditioned avoidance model. Furthermore, the compounds were tested in vivo for the development of catalepsy, which is a predictive parameter for extra-pyramidal side-effects caused by many antipsychotics. The investigated azecines displayed low cytotoxicity, and the affinities for human dopamine D1-D5 and serotonin 5-HT2 A receptors were in a nanomolar range. In vivo, their antipsychotic activities in the rat model were comparable with those of haloperidol and risperidone, but revealed a 2–5 times better therapeutic range with regard to catalepsy. Preliminary tests for oral bioavailability also revealed promising results for this new class of potential antipsychotic compounds. In conclusion, our in vivo experiments show that aromatic [d,g]-annelated azecines represent a novel and advantageous class of potential atypical neuroleptics.
- 5 April 2012
- Published by Georg Thieme Verlag KG in Arzneimittelforschung
- Vol. 62 (05) , 252-260
Molecular Combination of the Dopamine and Serotonin Scaffolds Yield in Novel Antipsychotic Drug Candidates - Characterization by in vivo Experiments
Serotonin and dopamine play an important role in the aetiology of schizophrenia. Combination of the structural scaffolds of both neurotransmitters in a single molecule lead to aromatic [d,g]-bisannelated azecine derivatives, which have been shown to be nanomolar to subnanomolar dopamine D1-D5 receptor antagonists with a preference for the D1 family. In this work the potential antipsychotic activity of some azecine derivatives was predicted by their dopamine receptor affinities obtained in vitro from radioligand binding experiments and conclusively confirmed in vivo (rats) by applying a conditioned avoidance model. Furthermore, the compounds were tested in vivo for the development of catalepsy, which is a predictive parameter for extra-pyramidal side-effects caused by many antipsychotics. The investigated azecines displayed low cytotoxicity, and the affinities for human dopamine D1-D5 and serotonin 5-HT2 A receptors were in a nanomolar range. In vivo, their antipsychotic activities in the rat model were comparable with those of haloperidol and risperidone, but revealed a 2–5 times better therapeutic range with regard to catalepsy. Preliminary tests for oral bioavailability also revealed promising results for this new class of potential antipsychotic compounds. In conclusion, our in vivo experiments show that aromatic [d,g]-annelated azecines represent a novel and advantageous class of potential atypical neuroleptics.
- 10 November 2011
- Published by Springer Nature
- p. 105-113
β-Carbolines: Occurrence, Biosynthesis, and Biodegradation
- 10 November 2011
- Published by Springer Nature
- p. 105-113
β-Carbolines: Occurrence, Biosynthesis, and Biodegradation
- 29 September 2011
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 54 (20) , 7422-7426
Chiral Indolo[3,2-f][3]benzazecine-Type Dopamine Receptor Antagonists: Synthesis and Activity of Racemic and Enantiopure Derivatives
Racemic and enantiopure 8-substituted derivatives of the lead dopamine receptor antagonist LE 300 (1) were prepared, and their affinities for the dopamine receptors (D1–D5) were tested. The separate enantiomers showed significantly different affinities; the (8S)-methyl and (8R)-hyroxymethyl derivatives where the substituents point below the reference plane of the indolo[3,2-f][3]benzazecine scaffold were markedly more active than their enantiomeric counterparts. The racemic 8-carboxy derivative was shown to be selective for the D5-receptor, even against D1.
- 29 September 2011
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 54 (20) , 7422-7426
Chiral Indolo[3,2-f][3]benzazecine-Type Dopamine Receptor Antagonists: Synthesis and Activity of Racemic and Enantiopure Derivatives
Racemic and enantiopure 8-substituted derivatives of the lead dopamine receptor antagonist LE 300 (1) were prepared, and their affinities for the dopamine receptors (D1–D5) were tested. The separate enantiomers showed significantly different affinities; the (8S)-methyl and (8R)-hyroxymethyl derivatives where the substituents point below the reference plane of the indolo[3,2-f][3]benzazecine scaffold were markedly more active than their enantiomeric counterparts. The racemic 8-carboxy derivative was shown to be selective for the D5-receptor, even against D1.
- 14 March 2011
- Published by Wiley in Chemistry & Biodiversity
- Vol. 8 (3) , 431-439
A Novel Non‐phenolic Dibenzazecine Derivative with Nanomolar Affinities for Dopamine Receptors
Dibenzazecines are a novel class of dopamine receptor antagonists, characterized by their high affinities as well as their tendency for D1 selectivity. Hitherto, the most active dibenzazecines were phenolic in nature; a 3-OH substituent was found to result in the highest affinities. However, the phenolic nature of these compounds mostly renders them unsuitable for in vivo application, due to the poor pharmacokinetic profile, imparted by the phenolic group. A novel dibenzazecine derivative was prepared, with methylenedioxy moiety, connecting C(2) amd C(3), instead of the 3-OH group. The newly synthesized derivative 3 showed high affinities similar to the lead LE404, displaying nanomolar affinities for all dopamine receptor subtypes. Its dibrominated derivative 4, though exhibiting almost a fivefold decrease in affinities, still displayed nanomolar ones for all dopamine receptors, except for D4. In a functional Ca2+ assay, both compounds 3 and 4 were found to possess antagonistic properties towards the dopamine receptors.
- 14 March 2011
- Published by Wiley in Chemistry & Biodiversity
- Vol. 8 (3) , 431-439
A Novel Non‐phenolic Dibenzazecine Derivative with Nanomolar Affinities for Dopamine Receptors
Dibenzazecines are a novel class of dopamine receptor antagonists, characterized by their high affinities as well as their tendency for D1 selectivity. Hitherto, the most active dibenzazecines were phenolic in nature; a 3-OH substituent was found to result in the highest affinities. However, the phenolic nature of these compounds mostly renders them unsuitable for in vivo application, due to the poor pharmacokinetic profile, imparted by the phenolic group. A novel dibenzazecine derivative was prepared, with methylenedioxy moiety, connecting C(2) amd C(3), instead of the 3-OH group. The newly synthesized derivative 3 showed high affinities similar to the lead LE404, displaying nanomolar affinities for all dopamine receptor subtypes. Its dibrominated derivative 4, though exhibiting almost a fivefold decrease in affinities, still displayed nanomolar ones for all dopamine receptors, except for D4. In a functional Ca2+ assay, both compounds 3 and 4 were found to possess antagonistic properties towards the dopamine receptors.
- 1 September 2010
- Published by Georg Thieme Verlag KG in Arzneimittelforschung
- Vol. 60 (09) , 544-552
Arylalkylamine-, β-carboline-, quinolizine- and azecine-derived compounds and their in vitro interaction with the ionotropic 5-HT3 receptor: search for new lead structures
Specific Serotonin receptor agonists and antagonists are marketed with respect to various diseases, most prominently severe emesis. To identify new chemical classes with affinity for the serotonin 5-HT3 channel, several compounds were synthesized which can be structurally classified as arylalkylamines, azecines, quinolizines and β-carbolines. These were tested in three models: 1. direct effect on ileum (overall model for contracting or relaxant effect), 2. antiserotoninergic effects on rat ileum (crude serotonin model), 3. inhibitory effect on the 5-HT3 receptor channel complex expressed in N1E-115 cells (serotonin-induced [14C]guanidinium influx (specific model)). Key findings and conclusion: Several azecine-type compounds exhibit 5-HT3 receptor channel antagonistic properties at concentrations close to that of tropisetron (used as a positive control) and might serve as potential lead structures for the development of further 5-HT3 channel receptor antagonists.
- 1 September 2010
- Published by Georg Thieme Verlag KG in Arzneimittelforschung
- Vol. 60 (09) , 544-552
Arylalkylamine-, β-carboline-, quinolizine- and azecine-derived compounds and their in vitro interaction with the ionotropic 5-HT3 receptor: search for new lead structures
Specific Serotonin receptor agonists and antagonists are marketed with respect to various diseases, most prominently severe emesis. To identify new chemical classes with affinity for the serotonin 5-HT3 channel, several compounds were synthesized which can be structurally classified as arylalkylamines, azecines, quinolizines and β-carbolines. These were tested in three models: 1. direct effect on ileum (overall model for contracting or relaxant effect), 2. antiserotoninergic effects on rat ileum (crude serotonin model), 3. inhibitory effect on the 5-HT3 receptor channel complex expressed in N1E-115 cells (serotonin-induced [14C]guanidinium influx (specific model)). Key findings and conclusion: Several azecine-type compounds exhibit 5-HT3 receptor channel antagonistic properties at concentrations close to that of tropisetron (used as a positive control) and might serve as potential lead structures for the development of further 5-HT3 channel receptor antagonists.